ICJEM

The Intercontinental Journal of Emergency Medicine aims to publish issues related to all fields of emergency medicine and all specialties involved in the management of emergencies in the hospital and prehospital environment of the highest scientific and clinical value at an international level and accepts articles on these topics.

EndNote Style
Index
Original Article
The relationship between mean platelet volume and CURB-65 in predicting hospitalization and 28-day mortality in COVID-19 pneumonia patients admitted to the emergency department
Aims: This study aimed to investigate the combined prognostic value of Mean Platelet Volume (MPV) and CURB-65 scoring in predicting hospital admission status and 28-day mortality among COVID-19 pneumonia patients admitted to the emergency department.
Methods: A prospective observational study was conducted on patients diagnosed with COVID-19 pneumonia in the Adult Emergency Medicine Clinic of Ankara City Hospital. Inclusion criteria included polymerase chain reaction (PCR) positivity and characteristic findings on thoracic computed tomography (CT). Clinical, laboratory, and radiological data were collected, and statistical analyses were performed using SPSS 22.0. ROC curve analysis evaluated the prognostic performance of MPV and CURB-65.
Results: Among 500 patients included in the study (55.8% male, mean age: 64 ± 14 years), 49 (9.8%) patients died within 28 days. Higher CURB-65 scores and MPV levels were significantly associated with increased 28-day mortality (p<0.001 and p=0.019, respectively). Comorbidities such as coronary artery disease, hypertension, cancer, heart failure, and stroke history were also significant predictors of mortality (p<0.05). Patients with CURB-65 scores ?3 and elevated MPV values had a markedly increased mortality risk. Moreover, thoracic CT findings such as diffuse infiltration and consolidation correlated significantly with poor outcomes (p=0.017 and p=0.001, respectively).
Conclusion: The combined use of CURB-65 and MPV offers a valuable tool for predicting 28-day mortality in COVID-19 pneumonia patients. These findings suggest the need for further studies to validate the utility of this combined approach in clinical practice.


1. Ahn DG, Shin HJ, Kim MH, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-324. doi:10.4014/jmb.2003.03011
2. Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767-772. doi:10.1016/j.cmi. 2020.04.012
3. Yu C, Lei Q, Li W, et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China. Am J Prev Med. 2020;59(2):168-175. doi:10.1016/j.amepre.2020.05.002
4. Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study.Clin Microbiol Infect. 2020;26(9):1242-1247. doi:10. 1016/j.cmi.2020.05.041
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
6. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis.Aging Dis. 2020;11(3):668-678. doi:10.14336/AD.2020.0502
7. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study.Lancet. 2020; 395(10238):1715-1725. doi:10.1016/S0140-6736(20)30854-0
8. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY.Nature. 2020;584(7821): 430-436. doi:10.1038/s41586-020-2521-4
9. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
10. Satici C, Demirkol MA, Sargin Altunok E, et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19.Int J Infect Dis. 2020;98:84-89. doi:10.1016/ j.ijid.2020.06.038
11. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.Clin Chem Lab Med. 2020;58(7):1021-1028. doi:10.1515/cclm-2020-0369
12. G&uuml;&ccedil;l&uuml; E, Kocayiğit H, Okan HD, et al. Effect of COVID-19 on platelet count and its indices.Rev Assoc Med Bras (1992). 2020;66(8):1122-1127. doi:10.1590/1806-9282.66.8.1122
13. Ceyhan MA, T&uuml;mer M, G&uuml;r&uuml; S, Kadı G, Demir GG. Mean platelet volume and red cell distribution width values in patients with COVID-19 admitted to intensive care units or wards from emergency department. Archives Curr Med Res. 2021;2(2):88-92. doi:10.47482/acmr.2021.20
14. Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia.Invest Radiol. 2020; 55(6):327-331. doi:10.1097/RLI.0000000000000672
15. Golcuk Y, Golcuk B, Bilge A, Irik M, Dikmen O. Combination of mean platelet volume and the CURB-65 score better predicts 28-day mortality in patients with community-acquired pneumonia.Am J Emerg Med. 2015;33(5):648-652. doi:10.1016/j.ajem.2015.02.001
Volume 3, Issue 3, 2025
Page : 46-51
_Footer